The detection and analysis of rare blood biomarkers is necessary for early diagnosis of cancer and to facilitate the development of tailored therapies. Nature Biomedical Engineering July 16, 2018 VIEW…
Glioblastoma is a rapidly progressing disease with poor outcome, with a median overall survival (OS) of less than 15 months for patients with newly diagnosed glioblastoma. Though glioblastoma is a…
Use of arsenic trioxide could extend survival of some glioblastoma patients by three to four times historic median PHOENIX, Ariz. - Oct. 17, 2017 - From Sherlock Holmes to Agatha…
Team develops new tool, LumosVar, for discerning genetic variants; more genomic sequencing needed for clinical application to cancer patients PHOENIX and LOS ANGELES — Oct. 26, 2017 — Precision Medicine…
Encouraging early results following timely treatment guided by comprehensive genomic sequencing PHOENIX, Ariz. - Oct. 25, 2017 - Several patients with recurring glioblastoma, a deadly brain cancer, survived for more…
Ivy internships prepare students for the rigors of human nervous system research PHOENIX, Ariz. — June 29, 2017 — Alena Gladwin and Tristan Neal have a far greater appreciation of…
Dr. Waldemar Priebe is a medicinal chemist with an interest in brain tumors, and a drug he discovered and developed is on its way to a clinical trial at MD…
Two studies by researchers at the Translational Genomics Research Institute (TGen) and the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger) provide insight on the evolution of glioblastoma…
Cancers evolve in rapidly changing environments from single cells into genetically heterogeneous masses. Darwinian evolution selects for survival of the fittest cells, that is, those that are best suited to…
High-grade gliomas are aggressive cancers that often become rapidly fatal. Immunotherapy using CD8+ cytotoxic T lymphocytes (CTLs), engineered to express both herpes simplex virus type 1 thymidine kinase (HSV1-TK) and…